The DOI matches its Crossref record.
Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.
Abstract
LBA1011 Background: BV (Avastin®), an anti-angiogenic monoclonal antibody that prevents the biologic activity of VEGF, significantly improves overall (OS) and/or progression-free survival (PFS) in four tumour types. In patients with mBC, the phase III study E2100 demonstrated that BV in combination with paclitaxel as 1st-line therapy resulted in superior PFS compared with paclitaxel alone (hazard ratio [HR] = 0.48 as per independent review).The AVADO study investigated the combination of BV and D as first-line therapy in patients with locally recurrent or mBC. Methods: This randomised, double-blind phase III study compared D 100mg/m2 plus PL with D plus either BV 7.5mg/kg or BV 15mg/kg. D was administered q3w for up to 9 cycles. BV/PL was administered q3w until disease progression or unacceptable toxicity. The 1° endpoint was PFS, with 2° endpoints of OS, time to treatment failure, best overall response, duration of response, and safety. Key eligibility criteria were HER2-negative, inoperable locally recurrent or mBC; no prior chemotherapy for advanced disease; ECOG PS 0–1; adequate LVEF, and no CNS metastases. Statistical assumptions: 80% power for a 2-sided unstratified log-rank test to detect a HR for PFS of 0.7, for each BV arm compared with the PL arm (overall α=5%). Results: March 2006 to April 2007, 736 patients in 24 countries were randomised. With median follow-up of ∼11 months PFS was statistically significantly superior for both BV containing arms compared with D alone. ORR was superior in both combination arms relative to D alone. OS is immature due to short follow up. Conclusions: Both doses of BV in combination with D significantly improved PFS and RR compared with D alone. BV added limited incremental toxicity relative to control. Safety results were comparable on the two BV arms and the overall findings did not reveal any new safety signals. D + PL D + BV7.5mg/kg D + BV15mg/kg All randomised patients (n) 241 248 247 PFS Unstratified HR vs D + PL (95% CI) 0.79 (0.63, 0.98) 0.72 (0.57,0.90) p-value (log-rank test)* 0.0318 0.0099 Stratified HR vs D + PL† (95% CI) 0.69 (0.54, 0.89) 0.61 (0.48, 0.78) p-value (log-rank test)* 0.0035 0.0001 Response rate (CR + PR) (%)‡ 44.4 - 55.2 63.1 p- value vs D + PL 0.0295 0.0001 Safety population (n) 233 250 247 Grade ≥3 adverse events (%) 67.0 74.8 74.1 Grade ≥3 hypertension (%) 1.3 0.4 3.2 Grade ≥3 arterial thromboembolic events (%) 0.4 − 0.4 − 0.4 Grade ≥3 GI perforation (%) 0.9 0.8 − 16.6 Grade ≥3 CHF (%) − 12.0 15.2 Grade ≥3 febrile neutropenia (%) Any grade 5 adverse event (up to 21 days after last dose) (%) 2.6 1.6 1.6 *p-values adjusted for multiple testing †pre-specified stratifiedanalysis with censoring for additional anti-neoplastic therapy that started prior to Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Roche Roche, sanofi-aventis Roche Roche, sanofi-aventis Roche Roche, sanofi-aventis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Self-citationBiology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
Anders, C. K., & Carey, L. A. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.008 · Cited by 625
Adverse effects of anticancer agents that target the VEGF pathway
Chen, H. X., & Cleck, J. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.94 · Cited by 560
Hapani, S., Chu, D., & Wu, S. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70112-3 · Cited by 430
Metadata
- Authors
- Miles, D., Chan, A., Romieu, G., Dirix, L. Y., Cortes, J., Pivot, X., Tomczak, P., Taran, T., Harbeck, N., & Steger, G. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-05-20
- Volume
- 26
- Issue
- 15_suppl
- Pages
- LBA1011-LBA1011
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2247075085
- Cited by
- 213
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. https://app.cochat.ai/papers/10.1200/jco.2008.26.15_suppl.lba1011
- The paper
- Miles, D., Chan, A., Romieu, G., Dirix, L. Y., Cortes, J., Pivot, X., Tomczak, P., Taran, T., Harbeck, N., & Steger, G. G. (2008). Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.26.15_suppl.lba1011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.